---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-023088"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:47:42.377918+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# 4DMT reports FY2023 net loss $100.8M; positive 4D-150 wet AMD data, Phase 3 plan Q1 2025

## Summary
- Net loss $100.8M in 2023; cash $299M at Dec 2023; Feb 2024 offering $281M net; runway into H1 2027.
- 4D-150 interim data in wet AMD: favorable safety, no significant inflammation; 24-week data reduced treatment burden vs aflibercept.
- Phase 3 trial for 4D-150 in wet AMD expected to start Q1 2025; FDA RMAT and EMA PRIME designations.
- Pipeline progress: 4D-710 CF positive interim data; 4D-310 Fabry cardiac improvements; IND for 4D-175 GA expected Q2 2024.
- Strategic partnerships: Astellas (up to $942.5M milestones) for ophthalmic vectors; Arbor for CNS gene editing.

## SEC filing metadata
- accession: 0000950170-24-023088
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017024023088/0000950170-24-023088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017024023088/fdmt-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-023088
- JSON: https://secwatch.observer/filing/0000950170-24-023088.json
- Plain text: https://secwatch.observer/filing/0000950170-24-023088.txt

## Key facts
- Earnings Releases
  4D Molecular Therapeutics, Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On February 29, 2024, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000095017024023088/0000950170-24-023088-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.